In the BioHarmony Drug Report Database

"Preview" Icon

Lurbinectedin

Zepzelca, Lurbinectedin (lurbinectedin) is a small molecule pharmaceutical. Lurbinectedin was first approved as Zepzelca on 2020-06-15. It is used to treat small cell lung carcinoma in the USA. Zepzelca’s patent is valid until 2024-12-13 (FDA).

 

Trade Name

 

Lurbinectedin
 

Common Name

 

lurbinectedin
 

ChEMBL ID

 

CHEMBL4297516
 

Indication

 

small cell lung carcinoma
 

Drug Class

 

Ecteinascodin derivatives

Image (chem structure or protein)

Lurbinectedin structure rendering